Appili Therapeutics Inc (APLIF)
Appili Therapeutics Inc is a biopharmaceutical company focused on developing and acquiring medicines for infectious diseases with unmet medical needs in Canada. Its anti-infective pipeline includes ATI-1501, a taste-masked oral reformulation of metronidazole designed for anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a topical paromomycin formulation being developed for cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine candidate for francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada. Appili Therapeutics shares trade as common stock on OTC Markets.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-APLI.F
|
$0.0095
|
-5.0% Downside
|
Fair
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 13, 2026
|
-0.5x
|
-0.1x
|
8.1x
|
1.412 M
|
10.696 M
|
86.9%
|
89.1%
|
-200.8
|
—
|
31.5%
|
